Preferred Label : relatlimab;
MeSH Related Number : AF75XOF6W3;
Origin ID : C000721227;
UMLS CUI : C4724799;
ATC code(s)
- Currated CISMeF NLP mapping
- MeSH term(s) associated for indexing
- Pharmacological action(s)
- Record concept(s)
- Semantic type(s)
- UMLS correspondences (same concept)
https://www.has-sante.fr/jcms/p_3490820/fr/opdualag-nivolumab/relatlimab-melanome
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
drug combinations
relatlimab
nivolumab and relatlimab
Nivolumab
Antineoplastic Agents, Immunological
infusions, intravenous
Unresectable Cutaneous Melanoma
adult
adolescent
PD-L1 Expression Less than 1 Percent
Advanced Cutaneous Melanoma
evaluation of the transparency committee
melanoma
---
https://ansm.sante.fr/tableau-marr/nivolumab-relatlimab
2024
false
false
false
France
French
patients guideline
Drug-Related side effects and adverse reactions
Drug-Related side effects and adverse reactions
signs and symptoms
drug information
drug combinations
Nivolumab
relatlimab
---
https://www.ema.europa.eu/en/medicines/human/EPAR/opdualag
2022
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug combinations
Relatlimab
Relatlimab
Nivolumab
Nivolumab
Antineoplastic Agents, Immunological
nivolumab and relatlimab
melanoma
product surveillance, postmarketing
Advanced Cutaneous Melanoma
Metastatic Cutaneous Melanoma
Unresectable Cutaneous Melanoma
adolescent
adult
Immune Checkpoint Inhibitors
Immune Checkpoint Inhibitors
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized
PD-L1 Expression Less than 1 Percent
infusions, intravenous
programmed cell death 1 receptor
receptors, immunologic
Lag3 protein, human
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
relatlimab
relatlimab
---
